Cargando…

Therapeutic Effect of Sodium Selenite and Zinc Sulphate as Supplementary with Meglumine Antimoniate( Glucantime®) Against Cutaneous Leishmaniasis In BALB/C Mice

BACKGROUND: Successful therapy of leishmaniasis depends on effective cellular immune response. We evaluated the effectiveness of sodium selenite and zinc sulphate as known immunomodulator materials, in combination with Glucantime® in treatment of cutaneous leishmaniasis lesions resulting from Leishm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sorkhroodi, F Zamani, Naeini, AM Alavi, Ramazani, AR Zahraei, Ghazvini, MR Aghaye, Mohebali, M, Keshavarz, SA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tehran University of Medical Sciences 2010
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3279849/ https://www.ncbi.nlm.nih.gov/pubmed/22347250

Ejemplares similares

Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis
por: Layegh, Pouran, et al.
Publicado: (2011)

Therapeutic Potential of Green Synthesized Copper Nanoparticles Alone or Combined with Meglumine Antimoniate (Glucantime(®)) in Cutaneous Leishmaniasis
por: Albalawi, Aishah E., et al.
Publicado: (2021)

First Report on Infant Acute Urticaria after Mother’s Parenteral Use of Meglumine Antimoniate (Glucantime): A Case Report
por: MOZAFARI, Omid, et al.
Publicado: (2016)

Pharmacokinetics of neutron-irradiated meglumine antimoniate in Leishmania amazonensis-infected BALB/c mice
por: Borborema, Samanta Etel Treiger, et al.
Publicado: (2019)

Biodistribution of meglumine antimoniate in healthy and Leishmania (Leishmania) infantum chagasi-infected BALB/c mice
por: Borborema, Samanta Etel Treiger, et al.
Publicado: (2013)

Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime(®)) and the recombinant Leish-110f(®) + MPL-SE(®) vaccine to treat canine visceral leishmaniasis
por: Miret, Jorge, et al.
Publicado: (2008)

FIRST REPORT ON OTOTOXICITY OF MEGLUMINE ANTIMONIATE
por: Valete-Rosalino, Cláudia Maria, et al.
Publicado: (2014)

Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis
por: Vargas, Deninson Alejandro, et al.
Publicado: (2019)

Hoigne Syndrome Caused by Intralesional Meglumine Antimoniate
por: Guarneri, Claudio, et al.
Publicado: (2017)

Evidence for Tissue Toxicity in BALB/c Exposed to a Long-Term Treatment with Oxiranes Compared to Meglumine Antimoniate
por: Oliveira, Luiz Filipe Gonçalves, et al.
Publicado: (2017)

Tissue distribution of residual antimony in rats treated with multiple doses of meglumine antimoniate
por: Coelho, Deise Riba, et al.
Publicado: (2014)

Immunotherapy Using Autoclaved L. major Antigens and M. vaccae with Meglumine Antimoniate, for the Treatment of Experimental Canine Visceral Leishmaniasis
por: Jamshidi, Sh, et al.
Publicado: (2011)

Effect of hydroalcoholic extract of Echinacea purpurea in combination with meglumine antimoniate on treatment of Leishmania major-induced cutaneous leishmaniasis in BALB/c mice
por: Sarkari, Bahador, et al.
Publicado: (2017)

Neutrophil Activation: Influence of Antimony Tolerant and Susceptible Clinical Strains of L. (V.) panamensis and Meglumine Antimoniate
por: Fernández, Olga Lucía, et al.
Publicado: (2021)

Gulucatime versus Glucantime: A Serious Warning on Counterfeit Medicines
por: Abtahi-Naeini, Bahareh, et al.
Publicado: (2019)

Inductively coupled plasma mass spectrometry method for plasma and intracellular antimony quantification applied to pharmacokinetics of meglumine antimoniate
por: Garay-Baquero, Diana J, et al.
Publicado: (2021)

Associated-risk determinants for anthroponotic cutaneous leishmaniasis treated with meglumine antimoniate: A cohort study in Iran
por: Aflatoonian, Mohammad Reza, et al.
Publicado: (2019)

Effect of levetiracetam drug on antioxidant and liver enzymes in epileptic patients: case-control study
por: Mahdavi, Atena, et al.
Publicado: (2020)

Comparison of Oral Zinc Sulfate with Systemic Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis
por: Yazdanpanah, Mohamad Javad, et al.
Publicado: (2011)

RESOLUTION OF CUTANEOUS LEISHMANIASIS AFTER ACUTE ECZEMA DUE TO INTRALESIONAL MEGLUMINE ANTIMONIATE
por: Vasconcellos, Erica de Camargo Ferreira e, et al.
Publicado: (2014)

Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)
por: Gómez, María Adelaida, et al.
Publicado: (2020)

Intralesional Meglumine Antimoniate: Safe, Feasible and Effective Therapy for Cutaneous Leishmaniasis in Bolivia
por: Rojas Cabrera, Ernesto, et al.
Publicado: (2022)

The Relationship Between Antioxidants and Inflammation in Children With Attention Deficit Hyperactivity Disorder
por: Namjoo, Iman, et al.
Publicado: (2020)

Downregulation of Calcineurin Gene Is Associated with Glucantime(®) Resiatance in Leishmania infantum
por: Bagher KHADEM ERFAN, Mohammad, et al.
Publicado: (2013)

Alterations in Evoked Otoacoustic Emissions by the Use of Meglumine Antimoniate in American Tegumentary Leishmaniasis Patients
por: de Oliveira Bezerra, Débora Cristina, et al.
Publicado: (2017)

Embryonic toxico-pathological effects of meglumine antimoniate using a chick embryo model
por: Khosravi, Ahmad, et al.
Publicado: (2018)

Resistance of Leishmania (Viannia) Panamensis to Meglumine Antimoniate or Miltefosine Modulates Neutrophil Effector Functions
por: Regli, Ivo B., et al.
Publicado: (2018)

The effect of Nd:YAG laser therapy on cutaneous leishmaniasis compared to intralesional meglumine antimoniate
por: Omidian, Mohammad, et al.
Publicado: (2019)

A Novel Strategy for Enhance Potentiation of Meglumine antimoniate against Leishmania major In Vitro
por: MIRZAEI, Farzaneh, et al.
Publicado: (2019)

New onset of sinoatrial block in a young patient treated with systemic meglumine antimoniate
por: Daadaa, Najla, et al.
Publicado: (2021)

AgNP-PVP-meglumine antimoniate nanocomposite reduces Leishmania amazonensis infection in macrophages
por: Gélvez, Ana Patricia Cacua, et al.
Publicado: (2021)

A Comparison between the Effects of Glucantime, Topical Trichloroacetic Acid 50% plus Glucantime, and Fractional Carbon Dioxide Laser plus Glucantime on Cutaneous Leishmaniasis Lesions
por: Jaffary, Fariba, et al.
Publicado: (2016)

Evaluation of synergistic therapeutic effect of shark cartilage extract with artemisinin and glucantime on visceral leishmaniasis in BALB/c mice
por: Molaie, Soheila, et al.
Publicado: (2019)

Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate
por: Perez-Franco, Jairo E., et al.
Publicado: (2016)

Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis
por: Berger, Brandon A., et al.
Publicado: (2017)

Successful treatment by adding thalidomide to meglumine antimoniate in a case of refractory anthroponotic mucocutaneous leishmaniasis
por: Goyonlo, Vahid Mashayekhi, et al.
Publicado: (2019)

Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial
por: Lago, Jamile, et al.
Publicado: (2023)

Antileishmanial potentials of azacitidine and along with meglumine antimoniate on Leishmania major: In silico prediction and in vitro analysis
por: Derakhshani, Ali, et al.
Publicado: (2023)

In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate
por: Carrió, Jaume, et al.
Publicado: (2002)

Unresponsiveness to Glucantime Treatment in Iranian Cutaneous Leishmaniasis due to Drug-Resistant Leishmania tropica Parasites
por: Hadighi, Ramtin, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_id8fd712bfqk2snkvntvbfdt12